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ABSTRACT
Next-generation sequencing has dramatically increased genome-wide profiling 
options and conceptually initiates the possibility for personalized cancer therapy. 
State-of-the-art sequencing studies yield large candidate gene sets comprising 
dozens or hundreds of mutated genes. However, few technologies are available for 
the systematic downstream evaluation of these results to identify novel starting 
points of future cancer therapies.
We improved and extended a site-specific recombination-based system for 
systematic analysis of the individual functions of a large number of candidate genes. 
This was facilitated by a novel system for the construction of isogenic constitutive 
and inducible gain- and loss-of-function cell lines. Additionally, we demonstrate 
the construction of isogenic cell lines with combinations of the traits for advanced 
functional in vitro analyses. In a proof-of-concept experiment, a library of 108 isogenic 
melanoma cell lines was constructed and 8 genes were identified that significantly 
reduced viability in a discovery screen and in an independent validation screen. Here, 
we demonstrate the broad applicability of this recombination-based method and we 
www.impactjournals.com/oncotarget/              Oncotarget, 2017, Vol. 8, (No. 14), pp: 23760-23774
Research Paper
Oncotarget23761www.impactjournals.com/oncotarget
proved its potential to identify new drug targets via the identification of the tumor 
suppressor DUSP6 as potential synthetic lethal target in melanoma cell lines with 
BRAF V600E mutations and high DUSP6 expression.
INTRODUCTION
Since its advent, genome-wide mRNA expression 
profiling has been extensively used to compare tumors 
versus normal tissues, different stages of cancer 
progression, expression patterns associated with drug 
resistance and differences between cancer subtypes. 
In recent years, next-generation sequencing (NGS) 
techniques have further enabled researchers to sequence 
DNA and mRNA for mutations on genome-wide scale. 
Commonly, these approaches discover several hundreds 
of genes with recurrent mutations.
The first consensus mutational map generated 
using NGS identified 189 genes with potentially relevant 
mutations in driver genes of breast and colon cancer, most 
of which have an unknown role in cancer [1, 2]. Shah 
et al. recently identified more than 2,000 somatic single 
nucleotide variations including 107 insertion-deletion 
mutations in triple negative breast cancer [3]. In addition, 
four studies identified a cumulated set of 137 genes with 
potential driver mutations in melanoma [4–7]. Elucidating 
these genes` functions and interplay is a critical step 
towards the identification of novel starting points for 
therapy as, for example, demonstrated by the development 
of PARP-inhibitors for BRCA1/2-deficient tumors [8].
To translate the results of mutation screens into 
clinical applications, in-depth characterization of the 
phenotypic effect of each mutation is essential. However, 
systematic downstream functional analysis is rarely 
considered and evaluation commonly limited to a single 
or few genes [1–7]. The lack of comprehensive functional 
approaches may partially be due to limitations of existing 
strategies. Conceptually, lentiviral systems may enable 
functional studies of large gene sets as they enable efficient 
stable genomic insertion even in non-dividing cells [9]. A 
major drawback of this method is that multiple insertions 
may occur in a cell, leading to unaccounted copy-
number variation effects. Moreover, the random genomic 
integration may create a highly heterogeneous population.
Alternatives that overcome these limitations of 
lentiviral systems are genome-editing techniques based 
on, for example, zinc finger nucleases, CRISPR/Cas9 or 
Transcription Activator-Like Effector Nucleases (TALENs). 
They enable targeted insertion of genetic changes with high 
precision at single nucleotide-level. In contrast to lentiviral 
systems, genome editing allows for the creation of isogenic 
cells which differ only in the introduced genetic alteration. 
However, the efficacy of these techniques is variable and 
often in the lower percent range [10–14].
Site-specific recombination-based systems, such as 
the Flp-FRT [15] and the Cre-lox system [16], facilitate 
stable insertion of a recombinase recognition sequence 
(FRT- or lox-site) into the host cell genome. These 
sequences can consecutively be used to insert genes into 
the prepared chromosomal site, allowing for the derivation 
of isogenic cell lines with high efficacy.
Due to the high degree of standardization, we 
expected this technique to be suitable for serially 
analyzing large gene sets. First, we optimized an existing 
site-specific recombination-based system for the rapid and 
effective construction of isogenic cell line panels. Second, 
we extended this system to simplify cell line construction 
with either constitutive or inducible expression of a 
single gene or two genes of interest. Subsequently, we 
demonstrated the successful recombination at a single 
genomic location in a number of cell lines of different 
cancer types. We then selected one of these cell lines, 
A375, as a representative for a proof-of-concept screen, 
in which we constructed more than a hundred isogenic 
melanoma cell lines. An independent repetition of the 
cell line construction procedure was conducted for a 
subset of these genes to demonstrate the reproducibility 
of the results. Finally, the top five growth-suppressing 
genes were further characterized by cell cycle analysis 
and by generating cell line recombinants for cell lines of 
other cancer types. A main finding of additional proof-
of-concept experiments was that the tumor suppressor 
DUSP6 could serve as a potential synthetic lethal drug 
target in melanoma with BRAF V600E mutations.
RESULTS
Re-design of site-specific recombination systems
Site-specific recombination has been used for 
various applications, such as, an endogenous sequence of 
the host cell genome used for the insertion of sequences 
of interest (e.g. the rosa locus in mice) [17]. Moreover, 
exogenous sequences like FRT- or lox-sites can be 
stably integrated for subsequent gene insertion [15–17]. 
Remarkably, these techniques have been used extensively 
for generating transgenic mice, but have not been 
exploited for in vitro functional genomics approaches.
We initially used the commercially available Flp-
In system (Life Technologies). The system provides 
a plasmid (pFRT/lacZeo) to first insert the FRT 
recombination site into the host cell genome. The FRT-
site locates between a cytomegalovirus (CMV) promoter 
with an ATG start codon that drives expression of a 
lacZ-zeocin resistance fusion gene. Our goal was to 
insert an expression plasmid hosting a gene of interest 
as well as a hygromycin resistance gene using the Flp 
recombinase. The inserted genes would be under the 
control of the CMV promoter and start codon, thereby 
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eliminating the expression of the zeocin resistance fusion 
gene. Accordingly, the absence of lacZ positive and 
zeocin resistant cells, and the presence of hygromycin 
resistance would indicate successful transfections. As no 
correspondingly modified cancer cell lines are available, 
we transfected the frequently used cancer cell lines A375 
(melanoma), MCF7 (breast cancer), U251-MG (brain 
cancer), and A549 (lung cancer). Unfortunately, repeated 
transfections with the pFRT/lacZeo plasmid yielded low 
numbers of lacZ-positive cells in three of the four cell 
lines (Figure 1). Moreover, attempts to generate stable 
isogenic cell lines via site-specific recombination did not 
result in any hygromycin-resistant cells (data not shown).
We therefore created new vectors in which the ATG-
FRT cassette was placed upstream of an EGFP reporter 
using pEGFP-N1 (Clontech) as the backbone (Figure 2A, 
Supplementary Figure 1 and Supplementary Table 1). 
This configuration substituted the lacZ-zeocin resistance 
fusion gene with EGFP and a separate, i.e. non-fused, 
neomycin resistance gene. One vector variant (pRAPacc1) 
was equipped with the CMV promoter, while the other 
(pRAPacc2) contained the elongation factor 1-alpha 
(E1Fα) promoter. Using these newly generated vectors, 
reporter-positive cells were generated with 15- to 188-fold 
increased efficacy compared to the original system and, 
in addition, stably transfected clones of A549 cells were 
obtained which was not achieved with the pFRT/lacZeo 
system (Figure 1).
We further modified the expression plasmids 
(referred to as pRAPtar vectors) to enable serial 
construction of cell lines with constitutive and inducible 
expression of single or multiple genes. The pRAPtar-1c 
was designed for constitutive expression of target genes, 
while pRAPtar-1i contained a doxycycline (dox)-inducible 
promoter and a Tet-repressor in cis to provide isogenic 
cells with inducible expression in a single recombination 
step (Figure 2A and 2B, Supplementary Figure 1). The 
latter is particularly useful when studying cancer-related 
genes, since their constitutive expression often causes 
increased cell death.
In addition to the recombination-activated hygromycin 
resistance gene, we inserted a lox71-site [16] preceded by 
an SV40 promoter and an ATG start codon. As a result, the 
introduction of the first plasmid established a secondary 
recombination site suitable for the insertion of a plasmid 
via Cre-lox-mediated recombination. Consequently, 
a constitutive (pRAPtar-2c) and an inducible version 
(pRAPtar-2i) of the corresponding expression vector were 
generated. These carried a lox66-site preceding a start-
codon-deficient puromycin resistance gene (Figure 2A, 
Supplementary Figure 1). Thus, successful Cre-mediated 
recombination yielded puromycin-selectable cells. Finally, 
the pRAPtar-2 vectors further contain a third recombination 
site (phiC31 attP site) [18] to theoretically allow for the 
consecutive insertion of another sequence (Figure 2B, 
Supplementary Figure 1).
Accordingly, following stable insertion of the 
pRAPacc vectors to provide a so-called acceptor cell line 
(ACL), the system allows for constructing isogenic single 
recombinant cells (ISRs) via Flp-recombinase that have 
constitutive or inducible expression of a target sequence. 
Depending on whether a gene or a knockdown construct 
Figure 1: Vector performance in generating FRT-site modified acceptor cell lines. Four cancer cell lines were transfected 
under identical conditions with either pFRT/lacZeo from the commercially available Flp-In system or with pRAPacc1 or 2. After two weeks 
of selection, the number of lacZ-positive (pFRT/lacZeo) and of EGFP-positive cells (pRAPacc1/2) was scored. Values are averages of at 
least two independent experiments. Error bars represent standard error of the mean (SEM).
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(e.g. shRNA or pri-miRNA) is inserted, this results in a cell 
line for subsequent gain- or loss-of-function studies (Figure 
2B). Consecutively, ISRs can be used to insert a second 
sequence expressed in a constitutive or inducible fashion 
to obtain isogenic double recombinant cells (IDRs) with 
combinatorial traits (Figure 2B).
Construction of acceptor cell lines
We next constructed a panel of ACLs from 10 
commonly used cell lines of various cancer types (Table 
1). After transfection of pRAPacc vectors and selection 
of neomycin-resistant clones, we processed 16-54 stable 
EGFP-positive clones per cell line to identify cell lines 
suitable as ACLs for further studies.
We expected that some clones would host multiple 
insertions of vectors into the cell’s genome, compromising 
subsequent selection of positive recombinants and 
conceivably favoring undesired intra- or inter-
chromosomal recombination events. Thus, we tested an 
initial set of 374 individual clones for single integration 
via Southern blotting, yielding 70 clones (19%), for 
which single integration could be confirmed (Table 1, 
Supplementary Figure 2).
Next, the ability to accept an expression plasmid 
via Flp-mediated recombination was assessed, using the 
red fluorescent HcRed reporter gene cloned into pRAPtar-
1c. Most, but not all, of the clones (50 out of 70; 71%) 
readily delivered stable hygromycin-resistant ISRs, in 
which EGFP was switched off and the HcRed gene was 
Figure 2: Schematic survey of the system. (A) Display of the vectors with their most relevant elements. Recombination sites are 
indicated by blue triangles (1: FRT-site; 2: lox-sites; 3: phiC31 attP site for later expansion). White squares depict resistance genes for 
selection of isogenic single recombinant cells (ISRs; 1: hygromycin resistance gene) and isogenic double recombinant cells (IDRs; 2: 
puromycin resistance gene). Red squares symbolize the inserted target sequence, which could be either a gene or a shRNA-coding cassette 
for knockdown (1: target sequence for first insertion via Flp-FRT; 2: target sequence for second insertion via Cre-lox). (B) Schematic 
survey of part of the permutations of traits that can be generated. Recombination-mediated insertion of a pRAPtar-1 vector in the ACL 
genome yields selectable ISRs that lack green fluorescence and display either dox-inducible (I) or constitutive (C) expression of the target 
sequence. ISRs with overexpression of an open reading frame (ORF) or short hairpin RNA-mediated silencing of a gene (shRNA) would 
show gain (“+”) or loss of function (“-“). Consecutive Cre-mediated insertion of a pRAPtar-2 vector yields selectable IDRs with the desired 
combination of traits as exemplified for using the two inducible single recombinants.
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constitutively switched on (Table 1), as was determined 
by fluorescence microscopy.
We further analyzed the performance of the dox-
inducible expression vector. Consequently, we used the 
HcRed gene that was inserted in pRAPtar-1i via Flp-
recombinase for testing. Silencing and induction of 
red fluorescence was detected via microscopy and flow 
cytometry. The majority of the clones (42 out of 50; 84%) 
either displayed lack of suppression in the absence of 
dox or lack of induction after dox addition (summarized 
in Table 1). The remaining eight ACLs covered five 
different cancer cell lines (Table 1, Figure 3A and 3B, 
Supplementary Figure 3A). For a single ACL-pRAPtar-1i 
clone per cancer cell line we further confirmed inducible 
HcRed expression quantitatively in response to increasing 
amounts of dox (Figure 3C, Supplementary Figure 3B). 
In conclusion, from 374 clones eight ACLs were isolated 
for the subsequent construction of clones with functional 
constitutive and inducible gene expression. For five out of 
10 cancer cell lines, ACLs could be obtained that passed 
the described quality filters, corresponding to a 50% 
success rate.
Construction of isogenic single and double 
recombinant cells
To further test properties of the ACLs, we focused 
on A375-ACLN103 (melanoma) cells. Fluorescence 
microscopy and flow cytometry confirmed high and 
homogeneous expression after insertion of the HcRed 
gene via pRAPtar-1c recombination and quantitatively 
inducible expression after insertion of the HcRed gene 
via pRAPtar-1i recombination (Figure 3A-3C). We next 
inserted the TP53 gene cloned in pRAPtar-1i into the 
ACL genome and isolated six independent EGFP-negative 
clones (TP53-ISRs).
Southern blot analyses confirmed TP53 insertion 
exclusively into the genomic location flagged by the 
FRT-site (Figure 3D and 3E). We also inserted CDKN1A 
in pRAPtar-1i and tested inducible expression of the 
gene alongside TP53 expression in one of the TP53-
ISRs. Both clones displayed tunable mRNA expression 
levels in response to different dox concentrations 
and showed highly comparable induction kinetics 
(Figure 3F). In conclusion, the data indicated that ISRs 
demonstrated uniform induced expression as expected 
from isogenic cells.
Finally, we tested the construction of inducible 
double recombinants (IDRs) suitable to express 
combinatorial traits via Cre-mediated recombination. To 
facilitate this we used the A375-ACLN103 ISRs with 
inducible HcRed expression, as described above, and a 
commercially available EGFP-shRNA fusion construct 
which targets the cellular LMNA gene. The construct was 
cloned in pRAPtar-2i and -2c. Subsequently, IDRs were 
constructed which were expected to exhibit inducible 






Rec.+a Expr.+b ACL Name
Mewo Melanoma 42 13 4 0 -
SkMel28 Melanoma 20 4 3 0 -
A375 Melanoma 32 7 4 3 N103c, N104c, N120c
H1299 Lung cancer 48 6 6 1 B5c
A549 Lung cancer 53 12 12 1 X12d
MCF-7 Breast cancer 42 6 2 1 N107c
MDA-MB-231 Breast cancer 25 8 8 0 -
U87-MG Brain cancer 42 4 4 0 -
U138-MG Brain cancer 54 3 3 0 -
U251-MG Brain cancer 16 7 4 2 L106c, L1e
Total 10 374 70/374 50/70 8/50 5/10 cell lines
Success rate   19% 71% 16% 50%
a capable of accepting pRAPtar-1 vector by site-specific recombination as judged by obtaining hygromycin-selectable 
cells lacking green fluorescence; b capable of expressing target genes in an inducible fashion as judged by fluorescence 
microscopy and flow cytometry analysis with the HcRed reporter gene in pRAPtar-1i after dox induction; c generated with 
pRAPacc2; d generated with earlier variant of pRAPacc1 (pRAPacc1a) containing an additional TetR, which was non-
functional after stable insertion; e generated with pRAPacc1.
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HcRed fluorescence in conjunction with inducible 
or constitutive EGFP expression and parallel LMNA 
knockdown.
Resulting puromycin-resistant IDRs displayed 
the expected fluorescence patterns (Figure 4A and 
4B). qRT-PCR of three individual IDRs for each 
configuration further suggested uniform performance 
with downregulation of LMNA mRNA to 0.53- to 0.49-
fold for the IDRs with inducible EGFP-shRNA expression 
and 0.43- up to 0.16-fold for IDRs with constitutive 
EGFP-shRNA expression (Figure 4C). These results 
indicated that the system could be used efficiently to 
generate uniform isogenic cell lines with individual or 
combinatorial molecular traits.
Construction and screening of an isogenic 
melanoma cell line library
Our original objective was to develop a system for 
systematic functional analysis of large gene sets obtained 
from e.g. genome-wide sequencing studies reporting on 
recurrent mutations in tumor tissues [1–7]. To establish 
if our recombination system was able to analyze such 
large gene sets, we shuttled 108 genes including known 
tumor suppressors, oncogenes and randomly selected 
genes (Supplementary Table 2) into the pRAPtar-1i vector 
and subsequently inserted these into A375-ACLN103 
melanoma cells. For 95% of the selected genes point 
mutations and/or copy number variations in malignant 
Figure 3: Construction of isogenic single recombinants. Analyses used A375-ACLN103 cells. (A) Fluorescence microscopy of 
acceptor cell line A375-ACLN103 (ACL) and isogenic single recombinants with insertion by recombination of constitutively (ISR-1c) and 
dox-inducibly (ISR-1i) expressed HcRed. The phase contrast inlay (cropped) is to demonstrate the presence of cells. For ISR-1i images 
were taken 48 h after induction without (dox-) or with (dox+) 50 ng/ml doxycycline. Scale bars: 100 μm. (B) Flow cytometry analyses 
of HcRed expression for the corresponding ISRs and of EGFP expression for A375-ACLN103. (C) Flow cytometry analyses of HcRed 
expression in response to different dox concentrations depicted in ng/ml at the respective curve. The HcRed-negative ACL is included 
as negative control. (D) Configuration of pRAPacc inserted into the host cell genome (top left), part of pRAPtar-1i carrying the TP53 
open reading frame (top right) and after recombination of pRAPtar-1i into the FRT-site in the host cell genome (bottom). Yellow arrow: 
promoter; blue triangle: FRT-site; green square: EGFP; white square: hygromycin resistance gene; orange square: Tet-repressor. Correct 
insertion into the genome-localized FRT-site would combine two KpnI restriction sites in such way that a new and unique 2.5-kb restriction 
fragment emerges that can be detected with a radioactively labeled probe against the hygromycin resistance gene (indicated by the red line). 
(E) Southern blot analysis of KpnI-digested genomic DNA from six independent ISRs with insertion of TP53 cloned in pRAPtar-1i 
(ISR1-6), the A375-ACLN103 acceptor cell line used (ACL) and the original non-modified A375 cell line, probing the hygromycin 
resistance gene. M: size marker. (F) TP53 and CDKN1A were used to construct ISRs with pRAPtar-1i. Isogenic control recombinants 
(ISR-C) with insertion of the empty (i.e. ORF-deficient) pRAPtar-1i vector served as negative controls. Levels of mRNA expression were 
analyzed 48 h after induction with different dox concentrations by qRT-PCR. Error bars represent SEM.
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melanoma are reported according to the COSMIC 
database (http://cancer.sanger.ac.uk/cosmic) [19].
Transfection of A375-ACLN103 cells grown in 
two wells of a 6-well plate per gene was sufficient to 
yield at least three independent EGFP-negative ISR 
clones. Three clones per gene were consecutively pooled 
to minimize any potential random variation. Cells with 
insertion of the empty pRAPtar-1i vector served as 
isogenic controls (ISR-C), which allowed normalization 
for effects introduced by the vector system and/or by 
changes to the genomic insertion site. Subsequently, 
we analyzed changes in cell viability before and after 
induction of gene expression in a discovery screen. 
We identified 11 genes with significant growth-
suppressive effects compared to the isogenic controls 
(Figure 5A). Many of these effects are in accordance 
with current literature. For example, A375 cells harbor 
wild type TP53, expressed at substantial levels, but 
display comparably low CDKN1A (p21) protein levels 
[20]. Accordingly, TP53 overexpression did not cause 
significant changes in cell viability, while CDKN1A 
overexpression caused strong growth suppression. MYC 
has been reported to cause G2 cell cycle arrest in cells 
with wild type TP53 [21], which is in accordance with 
the significant suppression mediated by MYC in the 
discovery screen. The tumor suppressor PTEN exerted 
a moderate but significant growth suppressive effect 
(Figure 5A).
We selected a set of 26 genes, including the nine 
most prominent growth suppressors, for an independent 
validation by construction and screening of ISRs 
generated with A375-ACLN120 cells (Supplementary 
Table 3). Southern blot data indicated a different 
genomic insertion site as compared to A375-ACLN103 
cells (Supplementary Figure 2A and 2B) such that this 
independent approach was suitable to filter for effects 
on cell growth caused by the chromosomal location 
of the insertion site. The validation screen confirmed 
effects on growth for 25 out of 26 genes. Only DDX10 
was not confirmed, leading to a 96% confirmation 
rate and a Pearson correlation coefficient of 0.87 
(Figure 5B and 5C). In summary, this indicated that 
ISR libraries can be used efficiently to analyze large 
gene sets and to identify phenotypic effects in a robust 
fashion.
Identification of a potential tumor suppressive 
network
We selected a subset of the genes with confirmed 
growth suppressive effects for further analysis. 
First, we subjected the ISRs generated with A375-
ACLN103 to cell cycle analyses. CDKN1A, used as 
positive control, caused the expected G0/G1 arrest. 
Furthermore, the G2-arrest suggested in the literature 
for MYC overexpression in TP53 wild type cells was 
confirmed and accompanied by a significant increase 
of apoptotic cells (Figure 6A, Supplementary Figure 
4). Among the top five growth-suppressing genes 
tested, STARD8 and DUSP6, a commonly known tumor 
suppressor [22, 23], arrested cells in G1/G0-phase, 
while MAPRE3, RPS6KA2 and EMD induced apoptosis 
(Figure 6A, Supplementary Figure 4). Apoptosis-
inducing effects were also confirmed in independent 
assays by quantifying inter-nucleosomal genomic DNA 
degradation (Figure 6B).
Figure 4: Construction of isogenic double recombinants. The ISR with insertion of dox-inducible HcRed was used to 
generate IDRs via Cre-lox mediated recombination with either (A) dox-inducible (pRAPtar-2i) or (B) constitutive expression 
(pRAPtar-2c) of a second sequence. The sequence comprised an emerald GFP (EGFP) reporter gene linked to a cassette for 
expression of an shRNA targeting the cellular LMNA gene. (A) Fluorescence microscopy of IDRs with inducible EGFP-
shRNA cassette shows induction of both reporters (2 μg/ml dox for maximum induction). Scale bars: 100 μm. (B) Fluorescence 
microscopy of IDRs with constitutive EGFP-shRNA cassette 48 h post induction with 2 μg/ml dox and without induction. 
Scale bars: 100 μm. (C) Quantification of knockdown and overexpression in IDRs. Three clones each (C1-C3 and C4-C6, 
respectively) were analyzed for knockdown of LMNA and induction of HcRed mRNA expression by qRT-PCR. Values are 
referred to LMNA levels in the ISR with HcRed insertion only (without induction). Error bars represent SEM.
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These five genes were further utilized to construct 
ISRs from ACLs of the other three cancer types, using 
the inducible vector pRAPtar-1i, to investigate if the 
observed growth suppressive effects were melanoma-
specific. Tumor suppressive effects were confirmed 
for all five genes in at least one additional cancer type 
(Figure 6C). ISRs with EMD could not be constructed 
for the brain cancer U251-ACLL106, this was likely 
due to strong apoptotic effects exerted by low leaky 
expression levels in the absence of dox. Of note, in 
MCF7 breast cancer cells, STARD8 had a growth-
promoting effect as opposed to its tumor-suppressive 
function in melanoma and lung cancer.
GeneMANIA analysis (www.genemania.org) 
[24] further indicated that DUSP6, EMD, MAPRE3 
and RPS6KA2, but not STARD8, are linked in a tumor 
suppressive network as defined by known genetic, 
pathway and/or physical interactions (Figure 6D). Taken 
together, the data confirmed tumor suppressive functions 
for the five genes, however, STARD8 may function as 
context-specific tumor suppressor or oncogene. The 
unbiased screen identified a potential tumor suppressive 
network which may be relevant in various cancer 
types. However, these results have to be confirmed via 
functional studies.
The tumor suppressor DUSP6 is a putative 
synthetic lethal target in melanoma
Analyses in primary melanoma and melanoma cell 
lines indicated that MAPRE3 and EMD mRNA levels were 
not substantially changed compared to primary normal 
human epidermal melanocytes (NHEM). While STARD8 
levels were upregulated in primary tumors and decreased 
in cell lines (Figure 7A), RPS6KA2 levels were normal 
or decreased, however, DUSP6 mRNA expression was 
consistently elevated (Figure 7A).
Activating BRAF mutations, such as the common 
V600E mutation, result in increased MEK activation, 
which leads to ERK1/2 phosphorylation. Phospho-
ERK1/2 in turn activates downstream targets via 
phosphorylation, among these p90RSK3 which is coded 
by RPS6KA2. In this regulatory circuit, DUSP6 functions 
as tumor suppressor in limiting ERK1/2 activity via 
dephosphorylation (Figure 7B) [23, 25, 26]. In accordance 
with its role as an ERK1/2 downstream target, RPS6KA2 
Figure 5: Screen of a melanoma isogenic single recombinant cell library. (A) A library of 108 A375-ACLN103-derived ISRs 
was generated and subjected to a cell viability scan as the primary (discovery) screen. Cell viability is displayed relative to ISRs with the 
empty expression plasmid (pRAPtar-1i) inserted (ISR-C). Eleven primary hits, including known cancer genes like TP53, CDKN1A, PTEN 
and MYC, were identified. (B) Validation of a panel of 26 genes in independent ISRs generated with A375-ACLN120 cells. Data from 
primary screen is included for comparison. (C) Correlation plot of validation versus primary screen with Pearson correlation coefficient 
(PCC) of 0.87. Statistical significance was evaluated using two-tailed Student`s t-tests and is indicated by *: P < 0.05; **: P < 0.01; 
***: P < 0.001; ****: P < 0.0001. All error bars represent SEM.
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has been associated with oncogenic functions by various 
groups [27–29]. Here, our results indicated that increased 
p90RSK3 activity triggers apoptosis (Figure 6A and 
6B), suggesting that p90RSK3 may also function as a 
tumor suppressor in specific scenarios. Survival analyses 
available for breast and lung cancer patients [30] supported 
this hypothesis as high expression of both DUSP6 and 
RPS6KA2 were associated with significantly improved 
survival in both cancer types (Figure 7C).
We therefore hypothesize that elevated DUSP6 
levels in melanoma are one mechanism for compensating 
BRAF V600E hyperactivation, which might otherwise 
trigger apoptosis via ERK1/2 downstream targets. To 
investigate this, we performed an siRNA-mediated 
knockdown of DUSP6 in BRAF wild type melanoma. As 
expected for a tumor suppressor, the knockdown either 
promoted cell growth or did not exert any effect, while 
the same knockdown in BRAF V600E melanoma with 
high DUSP6 expression caused cell death via induction 
of apoptosis (Figure 7D-7G). This indicated inactivation 
of tumor suppressors, specifically DUSP6, as a counter-
intuitive, but conceivable, synthetic lethal therapeutic 
concept in a subset of melanomas.
DISCUSSION
Our present study was initiated to investigate how 
large gene sets, resulting from genome-wide cancer 
mutation screens, can be functionally analyzed with 
a high degree of efficiency and standardization. There 
is a continuously growing demand for such functional 
genomic approaches because large numbers of driver 
genes have been classified solely based on statistical 
analysis and bioinformatic filtering processes [1–7]. 
However, the vast majority of the identified genes and 
their mutations have unknown functions in general and 
in cancer in particular. Finally, as discussed below, the 
identification of oncogenes or tumor suppressors in one 
cancer (sub)type does not necessarily translate to other 
cancer (sub)types.
Figure 6: Identification of a tumor suppressive network. (A) Cell cycle distribution as mean of at least two independent experiments 
(background: A375-ACLN103). (B) Relative apoptosis activity as mean of two independent experiments (background: A375-ACLN103). 
(C) One ACL clone of each of the other three cancer backgrounds was used to create ISRs for the five genes and correspondingly matched 
negative controls (ISR-Cs). ISRs were subjected to cell viability analyses after induction with dox. The effect of EMD in U251-ACLL106 
could not be determined (ND) because here no ISR could be obtained. (D) Interaction network suggested by GeneMANIA tool (www.
genemania.org). Dark gray: query genes; light gray: interacting genes. Genetic, pathway and physical interactions are indicated by green, 
blue, and red lines, respectively. Statistical significance was evaluated using one-tailed Student`s t-tests for the relative apoptosis activity 
and otherwise using two-tailed Student`s t-tests and is indicated as *: P < 0.05; **: P < 0.01; ***: P < 0.001; ****: P < 0.0001; ns: not 
significant. All error bars represent SEM.
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Several strategies for systematic functional analysis 
are based on currently available techniques. Among 
these are genome-editing techniques that allow for the 
introduction of genetic changes to obtain isogenic cells. 
While these techniques provide site-specific integration 
they may require the screening of hundreds of cell clones 
to identify corresponding cells carrying the desired 
knockdown or specific mutation [10–14]. We propose the 
construction of accepter cell lines (ACLs), which greatly 
simplifies the subsequent insertion of one or several genes 
of interest. We demonstrate that the first step to creating 
suitable ACLs experiences the same low efficacy as 
genome-editing. Even with an improved vector system, 
it required scanning of 374 clones to derive 8 suitable 
ACLs, corresponding to an efficacy of 2%. However, 
the consecutive insertion of target genes into ACLs 
demonstrated a success rate of nearly 100%.
Within the >100 constructed ISRs, only an isogenic 
U251 cell line for induced overexpression of EMD 
could not be generated, conceivably due to the strong 
apoptotic effects caused by the gene. Thus, the proposed 
strategy enables the efficient generation of permanent 
isogenic cell line libraries, which can successively be 
interrogated into various functional assays to analyze 
effects on e.g. proliferation, invasion/migration, apoptosis, 
or tumorsphere formation. We analyzed effects on 
Figure 7: DUSP6 is a context-specific synthetic lethal target in melanoma. (A) mRNA expression levels for five genes in primary 
melanoma (top panel) and melanoma cell lines (bottom panel). Case numbers are provided in the diagrams and levels are normalized to the 
average of two independent samples of NHEM, which were set to 1.0 (not shown). Error bars represent minimum and maximum values. 
(B) Schematic extract from Ras/Raf/MEK/ERK signaling pathway. DUSP6 inhibits p90RSK3 (coded by RPS6KA2) activation via ERK1/2 
dephosphorylation. (C) Kaplan Meier plots for luminal A breast cancer patients (left panels; relapse-free survival) and lung cancer patients 
(right panels; overall survival). Patients are split according to high (red curve) and low (black curve) expression. HR: hazard ratio with 
95% confidence interval. (D) Western blot analyses of siRNA-mediated DUSP6 knockdown in four selected melanoma cell lines with 
confirmed BRAF mutation status [43]. U: untreated; Ctrl: non-targeting control siRNA; siDu1 and siDu2: two DUSP6-targeting siRNAs. 
(E) Relative cell viability after DUSP6 knockdown referred to Ctrl. (F) Time course of relative cell viability in the two susceptible cell 
lines, and (G) corresponding Caspase-3/7 activity assessed in parallel and normalized to cell viability. Statistical significance was evaluated 
using two-tailed Student`s t-tests and is indicated by *: P < 0.05; **: P < 0.01; ***: P < 0.001; ****: P < 0.0001. All error bars represent 
SEM unless otherwise indicated.
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cell viability as a typical readout and achieved a 96% 
concordance rate between the discovery screen and the 
validation screen in an independent ACL derived from 
A375 melanoma cells.
As proof of concept, we constructed an isogenic 
melanoma cell line panel for a set of 108 genes, which 
were subsequently analyzed in a cell viability screen. 
We acknowledge that cell viability encompasses only 
one functional aspect among many that contribute to 
tumorigenesis. However, once established, the cell 
line libraries can be extensively studied using various 
additional functional assays.
Our results further demonstrated that five genes 
selected for their strong effect on cell viability also 
exerted effects in other cancer types. One of the five genes 
was STARD8 (also known as DLC3), which functions 
as a Rho-specific GTPase-activating protein involved in 
endocytic trafficking [31]. Its inactivation may prevent 
EGFR degradation and interfere with adherens junction 
integrity, in particular with E-cadherin function [31, 32]. 
One study reported a tumor suppressive role of STARD8, 
which is in accord with our results in A375 cells [33]. 
However, Durkin et al. observed indications for a tumor 
suppressive role of STARD8 in MCF7 cells [33], whereas 
our results suggested a growth-promoting effect. The 
contrasting data could be a result of Durkin et al. using 
the longer DLC3α transcript variant [33], while we used 
the alternatively spliced shorter DLC3β variant. MAPRE3 
(also known as EB3 or EBF3) codes for a microtubule 
end-binding protein that stabilizes focal adhesions and 
has been demonstrated to trigger apoptosis in cancer types 
other than those analyzed here [34–36]. EMD codes for 
emerin, which is affected by mutations in X-linked Emery-
Dreifuss muscular dystrophy. While EMD-deficient 
fibroblasts were recently shown to proliferate abnormally 
[37], the gene has not yet been linked to cancer. No 
consistent pattern of changes in mRNA expression levels 
were observed for these three genes in melanoma, such 
that their putative role in this cancer type remains elusive.
We further analyzed DUSP6, which is a well-
described tumor suppressor engaged in a regulatory 
loop with ERK1/2. DUSP6 counteracts Ras/Raf/MEK/
ERK signaling by ERK1/2 desphosphorylation [23, 26]. 
In our study, it exerted tumor suppressive functions in 
all four cancer types analyzed. Notably, we uncovered 
an unexpected opportunistic oncogenic role for DUSP6 
that may involve downstream signaling via p90RSK3, 
which is activated by ERK1/2-mediated phosphorylation. 
Inactivation of p90RSK3 acts synergistically with EGFR-
inhibition, thus posing a potential synthetic lethal drug 
target for overcoming PI3K-inhibitor resistance in breast 
cancer [27, 28]. Of note, RPS6KA2 was also determined 
to be a downstream target of BMI1 in glioblastoma stem 
cells [29]. These findings indicate a role as an oncogene. 
In contrast, Bignone et al. reported that RPS6KA2 is a 
tumor suppressor that triggers G1-arrest and apoptosis in 
ovarian cancer [38].
We also observed RPS6KA2-mediated apoptosis in 
our studies, which led us to investigate the knockdown 
effect of the upstream tumor suppressor DUSP6, which 
we expected to result in RPS6KA2 hyperactivation 
via ERK1/2. Our hypothesis led to the identification of 
DUSP6 as a potential synthetic lethal target in melanoma 
with BRAF V600E mutation and high expression of 
DUSP6, suggesting that, in certain scenarios, this tumor 
suppressor may serve as drug target. This counter-
intuitive proposition might be supported by recent 
findings that indicate less strict delineations between 
tumor suppressors and oncogenes. The concept of TP53 
gain-of-function mutants has been revitalized and the 
functions of oncogenic TP53 are currently under intensive 
investigation [39–41]. Importantly, members of the 
DUSP protein family, including DUSP6, have recently 
been proposed as therapeutic targets for glioblastoma 
multiforme, where DUSP6 causes tumor-promoting 
effects and chemoresistance [42, 43].
A distinct advantage to the presented strategy 
is its support for studying combinatorial traits, e.g. by 
the overexpression of one target gene and the parallel 
knockdown of a second target gene. We demonstrated 
this by constructing IDRs with fluorescence reporter 
expression and a parallel LMNA knockdown via 
subsequent recombination of both target sequences into 
the ACL genome. Thus, the system can, in principle, be 
used for large combinatorial studies such as a systematic 
screen for synthetic lethal targets in cancer.
In conclusion, we demonstrate a robust and flexible 
strategy for the construction of isogenic cell line libraries 
and establish its applicability for systematically screening 
larger gene sets commonly recovered from genome-wide 
sequencing studies. The results of a systematic proof-of-
concept cell viability screen led to subsequent hypothesis-
based experiments, which identified DUSP6 as context-
specific synthetic lethal target in melanomas with BRAF 
V600E mediated ERK1/2 activation.
MATERIALS AND METHODS
Cell lines and patient samples
Cell lines from Table 1 were obtained and 
cultivated according to the instructions from ATCC. 
Primary melanoma samples and patient-derived melanoma 
cell lines are part of the panel previously described [44]. 
All tumor samples and clinical data were collected 
with Institutional Review Board approval and patient's 
informed consent.
Transfection of acceptor plasmids
For comparison of pRAPacc1/2 to the pFRT/lacZeo, 
2 x 106 cells were transfected with 4 μg plasmid DNA in 
100 μl Nucleofector Solution (Lonza) via nucleofection, 
applying the conditions recommended by the supplier. 
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Transfected cells were seeded into two wells of a 6-well 
plate per cell line and 24 h later zeocin or G418 selection 
was introduced at concentrations previously determined 
in titration experiments. After a further 48 h, cells were 
transferred to 10 cm cell culture dishes and cultivated 
for 2 weeks for subsequent counting of reporter-positive 
clones. Cells transfected with pFRT/lacZeo were evaluated 
by conventional β-Gal staining, while cells transfected 
with pRAPacc1/2, were scored according to the number 
of green fluorescent colonies observed by fluorescence 
microscopy. Experiments were performed 2-3 times to 
calculate average values.
Generation of isogenic recombinant cell lines
Genes were shuttled into pRAPtar-1/2 vectors via 
the GATEWAY system (Invitrogen) according to the 
instructions of the supplier. The respective expression 
plasmid DNA was mixed at 1:5 ratio with either pOG44 
for Flp-mediated recombination or pGK-Cre for Cre-
mediated recombination. Consecutively, 1 x 106 cells were 
seeded in 6-well plates and transfected with 5 μg plasmid 
mixture using Lipofectamine according to manufacturer’s 
instructions. Three days post transfection, the selection 
antibiotic was added (hygromycin for ISRs and puromycin 
for IDRs) according to individual optima determined for 
the ACLs. In the majority of the transfections at least three 
non-green fluorescent clones per 2 wells emerged, which 
were isolated and propagated separately until pooled 
for further analyses. For gene and cell line resources 
management, we utilized the OpenLabFramework 
software [45].
Southern blot analyses
Southern blot analyses were performed to identify 
ACLs with single integration and to confirm single insertion 
into the authentic locus for selected recombinants. For single 
integration 10 μg genomic DNA was digested with PstI and 
for single insertion 15 μg genomic DNA was digested with 
KpnI, followed by gel electrophoresis on 1.2 % agarose 
gels and conventional Southern blotting. Standard random 
hexamer-based radioactive labeling was applied to generate 
an EGFP-specific probe for analyses of ACLs and a probe 
targeting the hygromycin resistance gene for analyses of 
TP53-ISRs.
Knockdown constructs
We utilized the cassette of the BLOCK-iT™ Pol II 
miR-LMNA Validated miRNA Control Vector (Thermo 
Fisher Scientific), where the LMNA-targeting shRNA 
is cloned behind emerald GFP (EGFP). The insert 
was shuttled into pRAPtar-2i and -2c vectors, which 
consecutively were co-transfected with pGK-Cre plasmid 
into A375-ACLN103 ISR cells already carrying the 
inducible HcRed reporter in the first site. The HcRed ISR 
cells served as reference point for comparison in these 
analyses. Because use of pRAPtar-2i inserts a second Tet-
repressor and the two CMV promoters on pRAP-tar-1 and 
pRAPtar-2 might compete for each other, a higher dox 
concentration, arbitrarily set to 2 μg/ml, was used for these 
experiments.
Fluorescence microscopy
Images of fluorescent cell lines were taken at 60 
x magnification (scale bars provided in figures) with 
an Olympus IX71 microscope, using the filter sets 
U-MNIBA3 (green fluorescence) and U-MWU2 (red 
fluorescence) and the Cell soft pro software (Olympus) 
at uniform exposure times 500 ms for green and 1000 
ms for red fluorescence. Image acquisition of IDRs in 
Figure 3B was performed by using the automated contrast 
enhancement of the software due to weaker HcRed 
fluorescence in IDRs.
Quantitative reverse transcription 
polymerase chain reaction
For quantitative reverse transcription polymerase 
chain reaction (qRT-PCR) total RNA was purified using 
TRIzol reagent (Invitrogen), DNAse treated, and subjected 
to oligo-dT-primed reverse transcription according 
to standard protocols. Analyses were performed in 
triplicate wells with 10 ng cDNA, using Human ACTB 
and/or GAPDH Endogenous Control assays (Applied 
Biosystems) as references for normalization. The PCR was 
performed using a 7500 Real-Time PCR System (Applied 
Biosystems) under the following conditions: 60 ºC for 15 
min (1 cycle) and 95 ºC for 15 sec, 60 ºC for 1 min (40 
cycles). Data was analyzed using qbasePLUS evaluation 
software (Biogazelle). The following gene-specific assays 
(Applied Biosystems) were used: Hs99999147_m1 for 
TP53, Hs00355782_m1 for CDKN1A, Hs00153462_m1 
for LMNA, Hs00169257_m1 for DUSP6, and a custom-
made assay was used for HcRed mRNA detection (forward 
primer: 5’-GGAGAGAACCACCACCTACGA-3’; reverse 
primer: 5’-CCTCCAGGCTGGTGTCC-3’; labeled probe: 
FAM-5’-ACGGCGGCATCCTGA-3’–NFQ).
Flow cytometry
For flow cytometric analyses, cells were trypsinized 
to a single cell suspension, centrifuged (270 g for 5 min), 
resuspended in Hanks Balanced Salt Solution (HBSS) 
and stored on ice until analyzed with a FACSCalibur flow 
cytometer (Becton Dickinson). Cell debris and dead cells 
were excluded from the analyses via forward and side 
scatter parameters. EGFP was detected at 488 nm in the 
FL1 channel, while HcRed was detected at 640 nm in the 
FL4 channel. Per analysis 10,000 cells were evaluated. 
HcRed levels were analyzed after 48 h with induction by 
various dox-concentrations.
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For cell cycle analyses, we incubated the cells for 
4 days in the presence of 50 ng/ml dox. The cells (about 
5 x 105 cells) were then trypsinized, gently pelleted by 
centrifugation, and fixed with methanol for 6 h at -20 
°C. After removal of methanol, cells were resuspended 
in 7-aminoactinomycin D (7AAD) solution (5 μg/ml 
7AAD, 1 mg/ml RNase A in PBS) and incubated for 30 
min at 37 °C followed by 90 min at 4°C. Fluorescence 
was evaluated as described above (detection at 650 nm; 
FL3 channel).
Cell viability assays
We seeded 1,000 cells per well in 96-well plates 
and determined cell viability after 5 d incubation by 
addition of 20 μl CellTiter-Blue reagent (Promega) per 
well. After 3 h incubation, fluorescence was measured 
at 550/610 nm in a Fusion Fluorometer (Packard 
Biosciences). Wells containing medium but no cells and 
processed in parallel were used for blank subtraction. 
To determine relative cell viability robustly, we first 
calculated relative viability of ISR cells without dox 
addition and with addition of 50 ng/ml dox relative to 
two independent empty vector control ISRs (ISR-C) 
processed in parallel. We then calculated the ratio of 
dox+/dox- cell viability, which should normalize for 
all factors contributed by vector components and/or 
inherent random variation among ISRs. Experiments 
were performed at least three times in triplicate. In the 
primary screen, only ISRs, which displayed a 20% or 
more change in cell viability were tested for statistical 
significance against isogenic controls.
Apoptosis assays
Relative apoptosis activity was determined using 
the Cell Death Detection ELISAPlus Kit (Roche). In 
brief, 104 cells per well were seeded in 12-well plates 
and cells were induced with 50 ng/ml dox 24 h post 
seeding. Determination of apoptosis activity followed 
48 h post induction according to the instructions of the 
supplier. After subtraction of blank (medium-only) values, 
relative apoptosis activity was calculated normalized to an 
isogenic negative control cell line with the empty vector 
construct inserted (ISR-C).
Caspase-3/7 activity after DUSP6 knockdown 
was determined using the Apo-ONE Homogeneous 
Caspase-3/7 assay according to the protocol of the 
provider (Promega) and the fluorescence signal was 
detected at the wavelengths 485/535 nm with a Victor3 
multi-label counter (PerkinElmer). The Caspase signal 
was normalized to the relative cell number analyzed in 
parallel using the fluorometric CellTiter-Blue reagent 
(Promega) as described above and finally referred to the 
values obtained for the non-targeting negative siRNA 
control (see below).
DUSP6 knockdown
For DUSP6 knockdown, cells were 




sense: 5`-UUCAUCGACAGAUUGAGCUtc-3`), or the 
non-targeting AllStars negative control siRNA (Qiagen), 
respectively, using the Lipofectamine RNAiMAX 
transfection reagent (Invitrogen) according to manufacturer’s 
instructions. Transfection experiments were performed 
at least three times in triplicate in 24-well format using 
12,500 cells per well. The medium was replaced 24 h post 
transfection and cells were cultured for an additional 48 h 
for protein extraction or another 96 h for cell viability and 
apoptosis assays.
Western blot analyses
To confirm the knockdown of DUSP6, total 
protein was harvested with RIPA buffer 48 h post 
siRNA transfection. Proteins (20 μg per sample) were 
separated by SDS-PAGE via an 8 % Precise protein gel 
(Life Technologies) and blotted onto a Immobilon-P 
transfer membrane (Millipore). Detection of DUSP6 was 
performed using mouse monoclonal antibody (1:1000; 
Abcam ab54940) and HRP-conjugated rabbit anti-
mouse IgG (H+L) secondary antibody (1:5000; Jackson 
Immunoresearch 315-035-003), and finally visualized with 
SuperSignal West Dura Extended Duration Substrate (Life 
Technologies). The antibody was afterwards removed 
from the membrane with 10 M urea, 45 mM SDS followed 
by washing steps with 50 % ethanol, 10 % acetic acid. 
Consecutively, the membrane was re-probed with a mouse 
monoclonal anti-beta tubulin antibody (1:1000; Abcam 
ab7792) and the same secondary antibody as before to 
confirm equal loading amounts of protein lysate.
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